Korsana Biosciences Quarterly Income Statement
NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Korsana Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Korsana Biosciences generated $0 in revenue, down 100.0% from the same quarter a year earlier. Korsana Biosciences reported a net loss of $1.8 million, compared with a loss of $324,000 a year earlier. Diluted earnings per share came in at -$0.41.
Summary generated from market data by MetaCap's automated system. Methodology
Korsana Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.02M | 875.00K | 93.00K | 81.00K | 1.81M | 194.00K | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | -100.00% | -100.00% | -43.24% | +351.03% | — | — | — | — | — | — | — | — |
| Operating Expenses | 1.77M | 3.21M | 1.86M | 1.88M | 1.76M | 1.54M | 1.30M | 1.32M | 1.38M | 1.62M | 1.79M | 6.01M |
| Research & Development | 0 | 730.00K | 519.00K | 348.00K | 56.00K | 36.00K | 56.00K | 81.00K | 105.00K | 44.00K | 24.00K | 580.00K |
| Operating Income | -1.77M | -3.21M | -838.00K | -1.01M | -1.67M | -1.46M | 502.00K | -1.13M | -1.38M | -1.62M | -1.79M | -6.01M |
| Other Income (Expense) | 16.00K | 32.00K | 39.00K | 30.00K | 1.35M | 28.00K | 28.00K | 405.00K | 62.00K | 76.00K | 101.00K | 107.00K |
| Net Income | -1.75M | -3.18M | -799.00K | -976.00K | -324.00K | -1.43M | 530.00K | -723.00K | -1.32M | -1.54M | -1.69M | 7.57M |
| Net Income growth (YoY) | — | — | -250.75% | — | — | — | — | -109.56% | — | — | — | — |
| EPS (Basic) | -0.41 | -0.76 | -0.14 | -0.30 | -0.11 | -0.56 | 0.23 | -0.29 | -0.53 | -0.62 | -0.32 | 3.10 |
| EPS (Diluted) | -0.41 | -0.76 | -0.14 | -0.30 | -0.11 | -0.56 | 0.23 | -0.29 | -0.53 | -0.62 | 0.06 | 2.72 |
| Shares Outstanding (Basic) | 4.25M | 4.21M | — | 3.23M | 3.07M | 2.56M | — | 2.53M | 2.51M | 2.49M | — | 2.44M |
| Shares Outstanding (Diluted) | 4.25M | 4.21M | — | 3.23M | 3.07M | 2.56M | — | 2.53M | 2.51M | 2.49M | — | 2.79M |
| EBITDA | — | — | — | — | — | — | — | — | — | — | -1.79M | -6.01M |
| Operating Margin | — | — | -81.76% | -114.97% | -1797.85% | -1798.77% | 27.80% | -581.44% | — | — | — | — |
| Net Margin | — | — | -77.95% | -111.54% | -348.39% | -1764.20% | 29.35% | -372.68% | — | — | — | — |
This table shows 12 quarterly periods of Korsana Biosciences's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow KRSA's reporting calendar. What is a income statement?